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Abstract
Reliable measurement of total testosterone is essential for the diagnosis, treatment and prevention 
of a number of hormone-related diseases affecting adults and children. A mass spectrometric 
method for testosterone determination in human serum was carefully developed and thoroughly 
validated. Total testosterone from 100 μL serum is released from proteins with acidic buffer and 
isolated by two serial liquid–liquid extraction steps. The first extraction step isolates the lipid 
fractions from an acidic buffer solution using ethyl acetate and hexane. The organic phase is dried 
down and reconstituted in a basic buffer solution. The second extraction step removes the 
phospholipids and other components by hexane extraction. Liquid chromatography–isotopic 
dilution tandem mass spectrometry is used to quantify the total testosterone. The sample 
preparation is automatically conducted in a liquid-handling system with 96-deepwell plates. The 
method limit of detection is 9.71 pmol/L (0.280 ng/dL) and the method average percent bias is not 
significantly different from reference methods. The performance of this method has proven to be 
consistent with the method precision over a 2-year period ranging from 3.7 to 4.8% for quality 
control pools at the concentrations 0.527, 7.90 and 30.7 nmol/L (15.2, 228, and 886 ng/dL), 
respectively. This method provides consistently high accuracy and excellent precision for 
testosterone determination in human serum across all clinical relevant concentrations.
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1. Introduction
Concentrations of testosterone in serum aid in the diagnosis and treatment of diseases such 
as hypogonadism [1,2], polycystic ovary syndrome [3], androgen deficiency in men [4–7], 
precocious or delayed puberty [8–10], and certain cancers [11–14]. Research findings 
describe associations of testosterone concentrations in blood with diabetes [15, 16], 
osteoporosis [17], cardiovascular diseases [15,18] and increased mortality [19,20]. Such 
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associations have stimulated additional research studies and resulted in new clinical practice 
applications.
A common element to all these clinical and research applications is the need for reliable and 
accurate testosterone measurements. Considerable inaccuracy of testosterone assays has 
been described, especially at testosterone concentrations commonly observed in women and 
children [10,21–25]. Mass spectrometric methods were found to show improved accuracy 
and lower variability than immunoassays, especially at low testosterone concentrations 
[21,22,24]. This can be attributed in part to the higher specificity of this assay technology 
which is achieved by isolating the analyte from the sample matrix prior to analysis and by 
mass and structure-specific detection [26]. However, studies comparing routine clinical 
mass spectrometric assays against a reference measurement procedure showed inter-method 
variability in precision and accuracy [25]. Though less pronounced than the variability 
observed with immunoassays, the performance of many mass spectrometric assays remains 
inadequate for testosterone determination in all clinical and research settings. This created 
the need for developing new mass spectrometry-based methods for routine testing of 
testosterone that are suitable for measuring testosterone in men, women and children with 
appropriate accuracy, precision and throughput. To meet these needs, we developed a mass 
spectrometry-based method for the measurement of testosterone at all concentration levels in 
the general population.
2. Material and methods
2.1. Materials and chemicals
Testosterone traceable to Australian National Measurement Institute reference material 
(NMI M914) was obtained from Cerilliant (Round Rock, TX) and [2,3,4-13C3]-testosterone 
(13C3-testosterone) from IsoSciences (King of Prussia, PA). Ethyl acetate, hexane, 0.1% 
formic acid in acetonitrile, 0.1% formic acid in water, sodium acetate, and ammonium 
carbonate, glacial acetic acid, and ammonium hydroxide were acquired from Fisher 
Scientific (Suwannee, GA) and ethanol from Sigma-Aldrich (St. Louis, MO). All solvents 
were HPLC grade and chemicals were reagent grade. Steroids used for interference testing 
were obtained from Steraloids (Newport, RI), Sigma-Aldrich and Cerilliant and prepared at 
the concentration 6.93 nmol/L (200 ng/dL) in a solvent solution (water/acetonitrile/formic 
acid, 90:10:0.1, v/v/v).
Frozen human serum samples and charcoal processed (one time or six times) sera were 
purchased from Bioreclamation (Hicksville, NY). Three levels of quality control (QC) 
materials were prepared by pooling units of human sera from healthy donors (QC low: 0.527 
nmol/L or 15.2 ng/dL, QC medium: 7.90 nmol/L or 228 ng/dL, QC high: 30.7 nmol/L or 
886 ng/dL).
Commercially prepared, de-identified single donor human serum samples were obtained 
from several blood banks in the U.S. and serum specimens from a large study were used to 
evaluate the method. Study participants provided informed consent. The study protocol was 
approved by the CDC Research Ethics Review Board.
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Serum samples were thawed, mixed at room temperature and processed together with 
quality control samples, reagent blank, and calibrators. Calibrators were prepared in ethanol 
from 1 mg/mL certified testosterone solution with no more than 3 serial dilutions. Thirteen 
calibrator levels covering a range of 0.0347–34.7 nmol/L (1.00–1000 ng/dL) were processed 
together with each set of samples, quality control samples, and reagent blank. Samples and 
reagents were pipetted in 96-well plates (2 mL well volume, Seahorse Labware, Chicopee, 
MA) using a Hamilton Microlab STARLet Liquid Handler instrument (Reno, NV). The well 
plates were sealed using a PTFE coated sealing mat (ArctiSeal, Arctic White LLC, 
Bethlehem, PA). Serum samples (100 μL) and internal standard solution (IS, 13C3-
testosterone, 100 μL, 3.43 nmol/L or 100 ng/dL in ethanol) were combined and mixed for 30 
min at room temperature. Buffer solution (100 μL, 0.5 mol/L sodium acetate, pH 5.5) was 
added, and the sample solution was mixed for 2 h. Liquid–liquid extraction (400 μL, ethyl 
acetate: hexane, 60:40, v/v) was performed twice. The solvents of the combined organic 
layers were evaporated using a Genevac EZ-2 evaporation system (Valley Cottage, NY) and 
the sample extract was re-dissolved in buffer solution (150 μL, 0.2 mol/L ammonium 
carbonate, pH 9.8). The sample solution was extracted twice using hexane (300 μL each) 
and the combined organic layers were evaporated. The sample extract was reconstituted 
(150 μL, 0.1% formic acid in water: 0.1% formic acid in Acetonitrile, 80:20, v/v) for liquid 
chromatography tandem mass spectrometry (LC-MS/MS) analysis.
2.3. LC-MS/MS
Electrospray ionization LC-MS/MS analysis was carried out using an AB Sciex 5500 triple 
quadrupole mass spectrometry instrument (Foster City, CA) with a Shimadzu LC-10 AD VP 
HPLC system (Columbia, MD). Chromatographic separation was achieved at 40 °C using a 
reversed phase column (C18 Hypersil Gold, 50 × 3 mm, 3 μm, Fisher Scientific Suwanee, 
GA) protected by a guard column (10 × 3 mm, 3 μm) with the same material. The analyte 
was eluted from the column using a gradient with the eluent changing from 10% to 70% 
acetonitrile in water within 12 min. The column was washed for 3 min in 95% acetonitrile in 
water and equilibrated for 3 min at the initial eluent composition. Both solvents contained 
0.1% formic acid. The flow rate and injection volume were 500 μL/min and 40 μL, 
respectively. Total testosterone was detected by selected reaction monitoring (SRM) in the 
positive ion mode, quantified by the ion transition m/z 289 → 97 for testosterone and 292 → 
100 for IS. For confirmation of the analytes, the transitions m/z 289 → 109 for testosterone 
and 292 → 112 for IS were used.
The ionspray voltage and source temperature were 4.75 kV and 650 °C, respectively. 
Declustering, entrance and exit potentials were 96 V, 8 V and 12 V, respectively. Curtain 
gas, ion source gas 1, ion source gas 2, and collision gas were set to 45 psi, 35 psi, 55 psi, 
and 10 psi, respectively. The collision energies for quantitation ions of both testosterone and 
IS were 27 eV, and confirmation ions 31 eV.
2.4. Data analysis
The LC-MS/MS raw data were processed using Analyst software (version 1.5.1 or higher, 
AB Sciex, Foster City, CA). SAS (version 9.2) was used to define quality control limits and 
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to evaluate analytical runs against these limits using a multi-rule quality control approach 
[27]. The limit of detection was determined by using an AB Sciex 5500 triple quadruple 
instrument according to the procedures previously described [28].
We used the average sum of squared residuals (ASSR) and the average relative sum of 
squared residuals (RASSR) from 20 sets of calibration runs to choose the best fitting 
regression model from among linear and polynomial models with no weighting, weights of 
1/X, 1/X2, or 1/(Variance of Y). The ASSR was calculated by summing up the squared 
differences between the model predicted and observed Y values. The RASSR was calculated 
by dividing the ASSR by the average of the Y values. A linear calibration curve using a 
weight of 1/X was selected because this model had the smallest ASSR among all linear 
models and the second smallest RASSR among all models. Two quadratic models had 
slightly smaller ASSR values than the model chosen, but their RASSR values were larger 
than the RASSR values of the model chosen.
The measurement accuracy was calculated by analyzing 172 sera with reference values 
assigned by reference methods operated at CDC with the Joint Committee for Traceability in 
Laboratory Medicine (JCTLM) code C8RMP6 [29,30], NIST with the JCTLM code 
C4RMP2 [31] and the University of Ghent with the JCTLM code NRMeth-7 [32] as part of 
the CDC Hormone Standardization Program (Host) [29,33]. The measurement bias was 
assessed following CLSI protocol EP9-A2 [34] using a mean bias of ±6.4% against the 
reference method and a total error of ±16.7% for individual measurements as criteria 
[30,35]. Serum-based reference material SRM 971 at 2 concentrations was obtained from 
NIST, and ERM-DA345 and ERM-DA346 from LGC Standards for accuracy assessment. 
Correlation of our method with the reference methods using Deming regression and bias plot 
analysis was performed with Analyse-it (Analyse-it Software, Ltd., Leeds, United Kingdom, 
version 2.26).
Repeatability and method precision for low, medium and high QC pools were determined 
following CLSI protocol EP5-A2 [36] on 71 different days (two results on each of two runs 
per day) over a period of 2 years, using 3 calibrator lots and multiple operators.
Sample matrix effects (ME) were evaluated on 6 different matrices including ethanol, saline, 
one time charcoal processed serum, six times charcoal processed serum, male serum and 
female serum as previously described [30,37]. The ME was assessed using the following 
equation, ME% = B/A × 100, where B refers to the area count ratios of testosterone to 13C3-
testosterone obtained from samples in matrix and A in matrix free solution.
The extraction efficiency was assessed in triplicate using medium QC pools and adding the 
IS solution before sample preparation (A), and by adding the IS solution at the end of the 
sample preparation (B), before injecting the sample in the LC-MS/MS analysis. The 
efficiency was calculated using the following equation: measured value (B)/measured value 
(A) × 100.
Specificity was determined with two different approaches. In the first approach, potentially 
interfering compounds such as structural steroid analogs were added to samples to assess co-
elution, while in the second approach quantitation ion/confirmation ion (QI/CI) ratios 
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obtained with patient samples were compared against those obtained with calibrators for 
each analytical run. The testosterone QI/CI ratios of calibrators and of 56 serum samples 
from the same batch of the above accuracy testing experiment were compared. Co-elution 
was assumed when the QI/CI ratio differed more than 20% [30,38,39].
Method ruggedness was assessed by comparing measurement values of the medium QC 
obtained with the described method against those obtained after modifying 5 main sample 
preparation parameters. The first parameter (P1) is the equilibrium time, during which sera 
are incubated with IS to achieve equilibrium between free and protein-bound IS (incubation 
durations tested: 20, 30 and 40 min). The second parameter is the pH of the dissociation 
buffer (P2), which is used to release testosterone from sex hormone binding protein and 
other proteins (pH levels tested: pH 5.2, 5.5 and 5.8). The third parameter is the time 
allowed for removing testosterone from proteins (P3, incubation times tested: 90, 120 and 
150 min). The fourth parameter is the buffer concentration used to remove testosterone form 
proteins (P4, buffer concentrations tested: 0.3, 0.5 and 0.7 mol/L). The last parameter (P5) is 
the pH of buffer used in the second extraction step to remove polar lipids such as 
phospholipids (pH levels tested: pH 9.4, 9.8 and 10.2).
3. Results and discussion
The aim of this study was the development of an analytical method for measuring total 
testosterone in sera from men, women and children. Thus, this method needs to be able to 
measure this analyte over a wide concentration range starting at very low concentrations 
typically observed in children. The limits of detection (LOD) and quantitation (LOQ) [28] 
were determined to be 9.71 pmol/L (0.280 ng/dL) and 32.9 pmol/L (0.950 ng/dL), 
respectively. The linearity of this method was verified for the concentration range from 17.3 
pmol/L (0.500 ng/dL) to 45.1 nmol/L (1300 ng/dL). To assure accurate and consistent 
calibration over such a wide concentration range, we use 13 calibrator levels and apply a 
weighted linear regression model. The sensitivity and measurement range of our method is 
sufficient for measuring testosterone levels in the general population. The signal-to-noise 
ratio ranged from 4.7 to 11.7 for 20 donor samples with testosterone concentration from 50 
pmol/L to 140 pmol/L (0.40 to 4.10 ng/dL).
There was no undetectable testosterone concentrations in 250 individual donor samples from 
men and women age 6 years and older with serum testosterone concentrations ranging from 
0.03 nmol/L (0.920 ng/dL) to 35.49 nmol/L (1024 ng/dL) (Table 1). A representative LC-
MS/MS selected ion chromatograms of female samples were shown on Fig. 1.
The lack of sufficient accuracy and reliability of testosterone measurements is a major 
concern of the clinical and public health communities [40,41]. The Centers for Disease 
Control and Prevention is addressing this concern through its Hormone Standardization 
Program that evaluates assay accuracy using predefined performance criteria [35]. Using 
172 serum samples with target values assigned by the National Institute for Standards and 
Technology, the University of Ghent and the CDC reference method covering a 
concentration range from 0.145 nmol/L (4.19 ng/dL) to 34.9 nmol/L (1007 ng/dL) showed 
no significant difference between our method and established reference methods with 
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Deming regression (intercept: −0.01, 95% CI: −0.05–0.04 nmol/L, slope: 0.99, 95% CI: 
0.98–1.00, Fig. 2a) and with plot analysis (mean bias: −1.2%, 95%CI: −5.9–4.1%, Fig. 2b). 
Individual measurements on all 172 samples met the 16.7% total error criterion. The 
differences between target values of certified serum-based reference materials from NIST 
and LGC Standards are in average −1.3% (Table 2), which is within ±6.4% criterion for 
routine, clinical methods [30,35]. Furthermore, the mean bias observed with our method is 
smaller than those reported for other methods [25,42], especially at testosterone 
concentrations typically observed in women and children.
The consistency of measured values obtained after changing 5 sample preparation 
parameters suggests that this method is minimally affected by small variations in sample 
processing parameters (Fig. 3). This is reflected in part by the high long-term precision of 
this method. The method precision over 2 years covering 71 different days was 4.8%, 3.7%, 
and 3.8% for QC low, QC medium and QC high, respectively. The repeatability (within-run 
precision) was 3.7, 2.2, and 2.0% respectively. The method precision is well below the 
suggested maximum impression for total testosterone measurements of 5.3% [30,35] and 
smaller than the precision reported for other mass spectrometry methods [25,42].
Method sensitivity and precision can be affected by matrix effects that can cause ion 
suppression among other effects. The mean ME% determined in 6 different matrices is 
100.2% (95% CI: 98.7–101.8%) as studied previously [30]. The matrices include ethanol, 
saline, 1 time charcoal processed serum, 6 times charcoal processed serum, male serum and 
female serum [30]. These findings suggest that measurements are minimally affected by the 
sample matrix, which might explain in part the high accuracy and precision obtained with 
this method. This method contains two liquid–liquid extraction steps. In the first step, serum 
lipids are separated from polar components. In the second step, polar lipids such as 
phospholipids are largely removed from the sample extract as evidenced in reduction in 
SRM (m/z 184–184) and precursor-ion scanning (pre m/z 184) signals that are indicative for 
these types of lipids [43,44]. Polar lipids typically accumulate on the column, deteriorate the 
separation and increase the ion suppression. A second extraction to remove polar lipids 
improved levels of precision (especially at low testosterone concentrations) and consistency 
of the chromatographic separation, and it prolonged column lifetime by about 5 times. In 
addition, we do not use protein precipitation, which is another common sample preparation 
approach [45]. Because testosterone is mostly bound to serum proteins, protein precipitation 
without complete dissociation of testosterone from binding-proteins and incomplete 
equilibrium of the IS with the binding proteins may result in incomplete or inconsistent 
analyte recovery [33]. Therefore, omitting protein precipitation seems to partially contribute 
to the very low measurement precision observed over 2 years. Despite multiple extraction 
steps, the extraction efficiency is 73% (95% CI: 70–76%). This is sufficient for quantitative 
measurements of testosterone at low concentrations such as those observed on women and 
children.
Measurement specificity has been another concern with testosterone measurements. To 
assess for potential interferences with known and unknown compounds we applied two 
approaches for interfering testing. In the first approach, the 28 structural analogs we tested 
showed no interfering peak in the chromatograms for the quantitation and confirmation ions 
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(Table 3). The second approach was used to assess interferences from unknown compounds. 
The average QI/CI ratio calibrators was 0.98 (95% CI: 0.82–1.15) while the ratio in 56 
serum samples was in average 1.12 (95% CI: 1.08–1.15). The highest QI/CI ratio observed 
in an individual sample was 1.24, which is well-below the suggested maximum differences 
of 20% difference [30,38,39]. These findings suggest that this method is either minimally 
affected by interfering substances or that it is not at all affected. Interferences from 
components in serum separator tubes (SST) have been reported [46] but were not found with 
our method using BD Vacutainer® SST™ (Franklin Lakes, NJ) probably because of the use 
of different chromatographic conditions.
Some methods described in literature use derivatization procedures to enable analysis by 
GC-MS or to achieve higher sensitivity of LC-MS measurements [47–49]. Our method does 
not require derivatization, which minimizes complexity and facilitates automation. 
Furthermore, other methods employ ethers, such as methyl tertiary-butyl ether [24], diethyl 
ether [50], and diethyl ether/ethyl acetate mixtures [51] for the liquid–liquid extraction. 
However, these solvents are difficult to handle with automatic pipetting system and require 
special safety considerations. The solvents used in our method showed compatibility with 
automated liquid handlers and require fewer safety considerations than ethers [52–54].
The present method proofed a consistent result over a 2-year period at all concentration 
levels, as well as experimental variations with very minimal matrix effect and no or 
negligible difference for testosterone in neat and matrix. Measurement values obtained with 
this method are in high agreement with established reference methods [30] and meets 
performance criteria for accuracy used by the CDC Hormone Standardization Program [35]. 
This described method provides a consistently high accurate and sensitive LC-MS/MS assay 
for testosterone measurements in serum at all concentration levels typically observed in men 
as well as in women and children.
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LC-MS/MS selected ion chromatograms of the quantification transitions for testosterone 
(top) and IS (bottom) in a female patient serum sample (1.00 nmol/L, 29 ng/dL).
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Deming regression (a) and bias plot (b) between described method and an established 
reference method using 172 individual health patient serum sample.
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Ruggedness testing (n = 7; error bar: standard deviation). *Five main method parameters — 
P1: equilibration time of serum and internal standard (20, 30, and 40 min); P2: pH of 
dissociation buffer (5.2, 5.5, 5.8); P3: dissociation time of testosterone from binding proteins 
(90,120, and 150 min), P4: concentration of dissociation buffer (0.3, 0.5 and 0.7 mol/L); and 
P5: pH of deprotonation buffer (9.4, 9.8 and 10.2).
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Table 1
Serum testosterone concentrations in individuals at difference age groups and sex.
Age group Gender Testosteronemedian (range)
6–11 years Female (n = 50) 0.18 (0.03–0.91) nmol/L5.20 (0.92–26.14) ng/dL
Male (n = 50) 0.17 (0.06–10.77) nmol/L4.94 (1.75–310.63) ng/dL
18 years and older Female (n = 75) 0.80 (0.08–3.33) nmol/L23.02 (2.36–95.91) ng/dL
Male (n = 75) 18.06 (1.10–35.49) nmol/L520.93 (31.66–1023.74) ng/dL
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Table 2
Accuracy traceability to JCTLM listed materials and NIST serum reference materials.
Samples Certified value Measured value (N = 3) %Bias
ERM DA345 19.7 nmol/L
570 ng/dL
19.4 nmol/L (95% CI: 18.4–20.5)
560 ng/dL (95% CI: 530–590)
−1.8
ERM DA346 0.890 nmol/L
25.5 ng/dL
0.881 nmol/L (95% CI: 0.849–0.912)
25.4 ng/dL (95% CI: 24.5–26.3)
−0.4
SRM 971 M 22.3 nmol/L
643 ng/dL
22.5 nmol/L (95% CI: 21.9–23.0)
649 ng/dL (95% CI: 633–664)
0.9
SRM 971 F 0.961 nmol/L
27.8 ng/dL
0.926 nmol/L (95% CI: 0.739–1.11)
26.7 ng/dL (95% CI: 21.3–32.1)
−4.0
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Table 3
List of steroid hormones used in the interference analysis.
Steroids Formula Molecular weight Supplier
Estrone C18H22O2 270.4 Cerilliant
Estradiol C18H24O2 272.4 Cerilliant
5,16-Androstadien-3b-ol C19H28O 272.4 Steraloids
16, (5a)-Androsten-3-one C19H28O 272.4 Steraloids
4,16-Androstadien-3b-ol C19H28O 272.4 Steraloids
2,(5a)-Androsten-17-one C19H28O 272.4 Steraloids
Estriol C18H24O3 288.4 Cerilliant
Dehydroepiandrasterone C19H28O2 288.4 Cerilliant
Epitestosterone C19H28O2 288.4 Sigma-Aldrich
Trans-dehydroandrosterone C19H28O2 288.4 Sigma-Aldrich
Trans-androsterone C19H30O2 290.4 Sigma-Aldrich
5-Androstenediol C19H30O2 290.4 Steraloids
Androsterone C19H30O2 290.4 Cerilliant
Etiocholan-3a-ol-17-one C19H30O2 290.4 Sigma-Aldrich
Dihydrotesosterone C19H30O2 290.4 Cerilliant
17a-Ethinylestradiol C20H24O2 296.4 Sigma-Aldrich
19-Norethindrone C20H26O2 298.4 Sigma-Aldrich
D(−)-Norgestrel C21H28O2 312.4 Sigma-Aldrich
Progesterone C21H30O2 314.5 Cerilliant
5-Pregnen-3β-ol-20-one C21H32O2 316.5 Steraloids
Pregnenolone C21H32O2 316.5 Sigma-Aldrich
17α-Hydroxyprogesterone C21H30O3 330.5 Cerilliant
17α-Hydroxypregnenolone C21H32O3 332.5 Steraloids
Corticosterone C21H30O4 346.5 Cerilliant
11-Deoxycortisol C21H30O4 346.5 Cerilliant
Cortisone C21H28O5 360.4 Steraloids
Hydrocortisone C21H30O5 362.5 Steraloids
Dehydroepiandrosterone sulfate C19H28O5S 368.5 Steraloids
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